Jim McCollum, Co-founder & Board member, introduced LiquidVision, an eye drop regimen that might correct presbyopia. The drops would be administered daily, or as needed, with a duration of five hours or more. “We’re trying to complement other modalities out there,” he said. The company is working with a miotic/cyclopegic drug to create a “pinhole effect” and to deal with the accommodation. The firm completed a one-day Phase IIb trial in 2016, generating promising results with no serious adverse side effects. Presbyopia Therapies is beginning a Phase IIb trial this year, which should produce top-line data in the fourth quarter.